These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

63 related articles for article (PubMed ID: 9470238)

  • 21. Postmenopausal hormones and coronary artery disease: potential benefits and risks.
    Lobo RA
    Climacteric; 2007 Oct; 10 Suppl 2():21-6. PubMed ID: 17882668
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prophylaxis approach to a-symptomatic post-menopausal women: breast cancer.
    Aguas F; Martins A; Gomes TP; de Sousa M; Silva DP;
    Maturitas; 2005 Nov; 52 Suppl 1():S23-31. PubMed ID: 16126355
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Is the estrogen controversy over? Deconstructing the Women's Health Initiative study: a critical evaluation of the evidence.
    Harman SM; Naftolin F; Brinton EA; Judelson DR
    Ann N Y Acad Sci; 2005 Jun; 1052():43-56. PubMed ID: 16024750
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Post-menopausal hormone replacement therapy (cont'd): risk-benefit balance in the hot seat.
    Prescrire Int; 2004 Jun; 13(71):106-9. PubMed ID: 15233153
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hormone replacement therapy (HRT) and ischaemic heart disease: getting to the heart of the matter.
    Chew S; Ng SC
    Singapore Med J; 2002 Jan; 43(1):41-4. PubMed ID: 12008777
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Role of hormone replacement therapy in the prevention and treatment of menopausal osteoporosis].
    Landa MC
    An Sist Sanit Navar; 2003; 26 Suppl 3():99-105. PubMed ID: 14716362
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Menopausal complaints, oestrogens, and heart disease risk: an explanation for discrepant findings on the benefits of post-menopausal hormone therapy.
    van der Schouw YT; Grobbee DE
    Eur Heart J; 2005 Jul; 26(14):1358-61. PubMed ID: 15860515
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cognition and cognitive aging.
    Henderson VW
    Climacteric; 2007 Oct; 10 Suppl 2():88-91. PubMed ID: 17882681
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A comparative review of the risks and benefits of hormone replacement therapy regimens.
    Warren MP
    Am J Obstet Gynecol; 2004 Apr; 190(4):1141-67. PubMed ID: 15118656
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The role of menopausal hormone therapy in preventing osteoporotic fractures: a critical review of the clinical evidence.
    Col NF; Bowlby LA; McGarry K
    Minerva Med; 2005 Oct; 96(5):331-42. PubMed ID: 16227948
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Biological and practical aspects of hormone replacement therapy: an approach to cardiovascular disease prevention in postmenopausal women].
    da Silva PM
    Rev Port Cardiol; 1999 Nov; 18(11):1047-55. PubMed ID: 10608165
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparative cardiovascular effects of different progestins in menopause.
    Rosano GM; Fini M
    Int J Fertil Womens Med; 2001; 46(5):248-56. PubMed ID: 11720197
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The lost promise of hormone replacement therapy and heart disease.
    Maas AH
    Semin Vasc Med; 2004 May; 4(2):135-44. PubMed ID: 15478034
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Postmenopausal hormone therapy: new questions and the case for new clinical trials.
    Manson JE; Bassuk SS; Harman SM; Brinton EA; Cedars MI; Lobo R; Merriam GR; Miller VM; Naftolin F; Santoro N
    Menopause; 2006; 13(1):139-47. PubMed ID: 16607110
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The impact of risk status, preexisting morbidity, and polypharmacy on treatment decisions concerning menopausal symptoms.
    Col NF
    Am J Med; 2005 Dec; 118 Suppl 12B():155-62. PubMed ID: 16414342
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Hormonal supplements for postmenopausal women: no evidence of protection against cardiovascular disease].
    Stehouwer CD
    Ned Tijdschr Geneeskd; 2001 Jan; 145(2):61-4. PubMed ID: 11225257
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The neurology of menopause.
    Henderson VW
    Neurologist; 2006 May; 12(3):149-59. PubMed ID: 16688016
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Invited Commentary: Hormone therapy risks and benefits--The Women's Health Initiative findings and the postmenopausal estrogen timing hypothesis.
    Banks E; Canfell K
    Am J Epidemiol; 2009 Jul; 170(1):24-8. PubMed ID: 19468078
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Breast cancer and hormonal therapy.
    Conner P; Lundström E; von Schoultz B
    Clin Obstet Gynecol; 2008 Sep; 51(3):592-606. PubMed ID: 18677153
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Recency and duration of postmenopausal hormone therapy: effects on bone mineral density and fracture risk in the National Osteoporosis Risk Assessment (NORA) study.
    Barrett-Connor E; Wehren LE; Siris ES; Miller P; Chen YT; Abbott TA; Berger ML; Santora AC; Sherwood LM
    Menopause; 2003; 10(5):412-9. PubMed ID: 14501602
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.